Northwest Investment Counselors LLC Invests $89,000 in Pfizer Inc. (NYSE:PFE)

Northwest Investment Counselors LLC bought a new position in Pfizer Inc. (NYSE:PFE) during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 3,194 shares of the biopharmaceutical company’s stock, valued at approximately $89,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. GoalVest Advisory LLC boosted its stake in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares during the last quarter. Creekmur Asset Management LLC purchased a new position in shares of Pfizer in the 4th quarter worth approximately $32,000. VisionPoint Advisory Group LLC boosted its stake in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares during the last quarter. Tennessee Valley Asset Management Partners purchased a new position in shares of Pfizer in the 4th quarter worth approximately $36,000. Finally, DiNuzzo Private Wealth Inc. purchased a new position in shares of Pfizer in the 4th quarter worth approximately $37,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the topic of a number of research analyst reports. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, June 17th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price target (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Morgan Stanley lifted their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average price target of $35.86.

Pfizer Trading Up 2.2 %

Shares of PFE stock opened at $28.36 on Tuesday. The company’s fifty day simple moving average is $27.72 and its two-hundred day simple moving average is $27.70. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $37.80. The stock has a market capitalization of $160.68 billion, a price-to-earnings ratio of -472.50, a PEG ratio of 1.09 and a beta of 0.70.

Pfizer (NYSE:PFE) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business’s revenue for the quarter was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.23 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.37 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 14th. Stockholders of record on Friday, May 10th were issued a $0.42 dividend. The ex-dividend date was Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 5.92%. Pfizer’s payout ratio is currently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.